Back

A shorter duration of dual-antiplatelet therapy following percutaneous coronary intervention: a meta-analysis of randomized clinical trials

29 August 2025 (09:09 - 09:27)
Organised by: Logo
Congress Presentation Part of: Adjunctive antiplatelet therapy for patients undergoing percutaneous coronary intervention Adjunctive Pharmacotherapy ESC Professional Premium Access ESC Congress 2025 European Society of Cardiology

About the speaker

Photo
Doctor Thomas Fretz

Indiana University School of Medicine, Indianapolis (United States of America)

4 More presentations in this session

Presentation thumbnail
State-of-the-art lecture on adjunctive antiplatelet therapy for patients undergoing percutaneous coronary intervention
Professor D. Capodanno (Catania, IT)
Slides Video
Presentation thumbnail
Impact of antiplatelet pretreatment on stent thrombosis in patients undergoing PCI in real world practice: insight France PCI registry
Doctor G. Range (Chartres, FR)
Abstract Slides Video
Presentation thumbnail
Aspirin reloading before percutaneous coronary intervention on chronic aspirin therapy: reduced early ischemia without bleeding trade-off
Doctor W. Dai (Tianjin, CN)
Abstract Slides Video
Presentation thumbnail
12- vs. 1-month DAPT: comparative outcomes after aspirin cessation with HT supreme stent
Doctor T. Tsai (Galway, IE)
Abstract Slides Video

Access the full session

Session thumbnail
Adjunctive antiplatelet therapy for patients undergoing percutaneous coronary intervention
Video

The Event

Event poster

ESC Congress 2025

29 August 2025 09:09 CET
You may be interested in
thumbnail
Congress Presentation
Meta-analysis of 3-month vs 12-month dual anti-platelet therapy after percutaneous coronary intervention
thumbnail
Congress Presentation
A very short duration of dual-antiplatelet therapy following percutaneous coronary intervention: a meta-analysis of randomized clinical trials
thumbnail
Congress Presentation
A shorter duration of dual-antiplatelet therapy for percutaneous coronary intervention following acute coronary syndrome: a meta-analysis of randomized clinical trials

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources